Medical Care

Global Graft Versus Host Disease Treatment Market Research Report 2025

The global market for Graft Versus Host Disease Treatment was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Graft Versus Host Disease Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Graft Versus Host Disease Treatment.
The Graft Versus Host Disease Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Graft Versus Host Disease Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Graft Versus Host Disease Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie Inc.
Acrofan
Astellas Pharma Inc.
Bristol-Myers Squibb Company
ElsaLys Biotech SA
F. Hoffmann-La Roche AG
Johnson & Johnson
Mallinckrodft PLC
Merck & Co., Inc.
Mesoblast Limited
Neovii Biotech GmbH
Novartis AG
Ocugen, Inc.
Pfizer Inc
Pluristem Therapeutics Inc.
Samedan Ltd
Sanofi SA
Soligenix, Inc.
Segment by Type
Etanercept
Monoclonal Antibodies
Thalidomide
Tyrosine Kinase Inhibitors
mTOR Inhibitors
Segment by Application
Acute GVHD
Chronic GVHD
Prophylaxis GVHD
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Graft Versus Host Disease Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Graft Versus Host Disease Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Etanercept
1.2.3 Monoclonal Antibodies
1.2.4 Thalidomide
1.2.5 Tyrosine Kinase Inhibitors
1.2.6 mTOR Inhibitors
1.3 Market by Application
1.3.1 Global Graft Versus Host Disease Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Acute GVHD
1.3.3 Chronic GVHD
1.3.4 Prophylaxis GVHD
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Graft Versus Host Disease Treatment Market Perspective (2020-2031)
2.2 Global Graft Versus Host Disease Treatment Growth Trends by Region
2.2.1 Global Graft Versus Host Disease Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Graft Versus Host Disease Treatment Historic Market Size by Region (2020-2025)
2.2.3 Graft Versus Host Disease Treatment Forecasted Market Size by Region (2026-2031)
2.3 Graft Versus Host Disease Treatment Market Dynamics
2.3.1 Graft Versus Host Disease Treatment Industry Trends
2.3.2 Graft Versus Host Disease Treatment Market Drivers
2.3.3 Graft Versus Host Disease Treatment Market Challenges
2.3.4 Graft Versus Host Disease Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Graft Versus Host Disease Treatment Players by Revenue
3.1.1 Global Top Graft Versus Host Disease Treatment Players by Revenue (2020-2025)
3.1.2 Global Graft Versus Host Disease Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Graft Versus Host Disease Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Graft Versus Host Disease Treatment Revenue
3.4 Global Graft Versus Host Disease Treatment Market Concentration Ratio
3.4.1 Global Graft Versus Host Disease Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Graft Versus Host Disease Treatment Revenue in 2024
3.5 Global Key Players of Graft Versus Host Disease Treatment Head office and Area Served
3.6 Global Key Players of Graft Versus Host Disease Treatment, Product and Application
3.7 Global Key Players of Graft Versus Host Disease Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Graft Versus Host Disease Treatment Breakdown Data by Type
4.1 Global Graft Versus Host Disease Treatment Historic Market Size by Type (2020-2025)
4.2 Global Graft Versus Host Disease Treatment Forecasted Market Size by Type (2026-2031)
5 Graft Versus Host Disease Treatment Breakdown Data by Application
5.1 Global Graft Versus Host Disease Treatment Historic Market Size by Application (2020-2025)
5.2 Global Graft Versus Host Disease Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Graft Versus Host Disease Treatment Market Size (2020-2031)
6.2 North America Graft Versus Host Disease Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Graft Versus Host Disease Treatment Market Size by Country (2020-2025)
6.4 North America Graft Versus Host Disease Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Graft Versus Host Disease Treatment Market Size (2020-2031)
7.2 Europe Graft Versus Host Disease Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Graft Versus Host Disease Treatment Market Size by Country (2020-2025)
7.4 Europe Graft Versus Host Disease Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Graft Versus Host Disease Treatment Market Size (2020-2031)
8.2 Asia-Pacific Graft Versus Host Disease Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Graft Versus Host Disease Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Graft Versus Host Disease Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Graft Versus Host Disease Treatment Market Size (2020-2031)
9.2 Latin America Graft Versus Host Disease Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Graft Versus Host Disease Treatment Market Size by Country (2020-2025)
9.4 Latin America Graft Versus Host Disease Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Graft Versus Host Disease Treatment Market Size (2020-2031)
10.2 Middle East & Africa Graft Versus Host Disease Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Graft Versus Host Disease Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Graft Versus Host Disease Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie Inc.
11.1.1 AbbVie Inc. Company Details
11.1.2 AbbVie Inc. Business Overview
11.1.3 AbbVie Inc. Graft Versus Host Disease Treatment Introduction
11.1.4 AbbVie Inc. Revenue in Graft Versus Host Disease Treatment Business (2020-2025)
11.1.5 AbbVie Inc. Recent Development
11.2 Acrofan
11.2.1 Acrofan Company Details
11.2.2 Acrofan Business Overview
11.2.3 Acrofan Graft Versus Host Disease Treatment Introduction
11.2.4 Acrofan Revenue in Graft Versus Host Disease Treatment Business (2020-2025)
11.2.5 Acrofan Recent Development
11.3 Astellas Pharma Inc.
11.3.1 Astellas Pharma Inc. Company Details
11.3.2 Astellas Pharma Inc. Business Overview
11.3.3 Astellas Pharma Inc. Graft Versus Host Disease Treatment Introduction
11.3.4 Astellas Pharma Inc. Revenue in Graft Versus Host Disease Treatment Business (2020-2025)
11.3.5 Astellas Pharma Inc. Recent Development
11.4 Bristol-Myers Squibb Company
11.4.1 Bristol-Myers Squibb Company Company Details
11.4.2 Bristol-Myers Squibb Company Business Overview
11.4.3 Bristol-Myers Squibb Company Graft Versus Host Disease Treatment Introduction
11.4.4 Bristol-Myers Squibb Company Revenue in Graft Versus Host Disease Treatment Business (2020-2025)
11.4.5 Bristol-Myers Squibb Company Recent Development
11.5 ElsaLys Biotech SA
11.5.1 ElsaLys Biotech SA Company Details
11.5.2 ElsaLys Biotech SA Business Overview
11.5.3 ElsaLys Biotech SA Graft Versus Host Disease Treatment Introduction
11.5.4 ElsaLys Biotech SA Revenue in Graft Versus Host Disease Treatment Business (2020-2025)
11.5.5 ElsaLys Biotech SA Recent Development
11.6 F. Hoffmann-La Roche AG
11.6.1 F. Hoffmann-La Roche AG Company Details
11.6.2 F. Hoffmann-La Roche AG Business Overview
11.6.3 F. Hoffmann-La Roche AG Graft Versus Host Disease Treatment Introduction
11.6.4 F. Hoffmann-La Roche AG Revenue in Graft Versus Host Disease Treatment Business (2020-2025)
11.6.5 F. Hoffmann-La Roche AG Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Details
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Graft Versus Host Disease Treatment Introduction
11.7.4 Johnson & Johnson Revenue in Graft Versus Host Disease Treatment Business (2020-2025)
11.7.5 Johnson & Johnson Recent Development
11.8 Mallinckrodft PLC
11.8.1 Mallinckrodft PLC Company Details
11.8.2 Mallinckrodft PLC Business Overview
11.8.3 Mallinckrodft PLC Graft Versus Host Disease Treatment Introduction
11.8.4 Mallinckrodft PLC Revenue in Graft Versus Host Disease Treatment Business (2020-2025)
11.8.5 Mallinckrodft PLC Recent Development
11.9 Merck & Co., Inc.
11.9.1 Merck & Co., Inc. Company Details
11.9.2 Merck & Co., Inc. Business Overview
11.9.3 Merck & Co., Inc. Graft Versus Host Disease Treatment Introduction
11.9.4 Merck & Co., Inc. Revenue in Graft Versus Host Disease Treatment Business (2020-2025)
11.9.5 Merck & Co., Inc. Recent Development
11.10 Mesoblast Limited
11.10.1 Mesoblast Limited Company Details
11.10.2 Mesoblast Limited Business Overview
11.10.3 Mesoblast Limited Graft Versus Host Disease Treatment Introduction
11.10.4 Mesoblast Limited Revenue in Graft Versus Host Disease Treatment Business (2020-2025)
11.10.5 Mesoblast Limited Recent Development
11.11 Neovii Biotech GmbH
11.11.1 Neovii Biotech GmbH Company Details
11.11.2 Neovii Biotech GmbH Business Overview
11.11.3 Neovii Biotech GmbH Graft Versus Host Disease Treatment Introduction
11.11.4 Neovii Biotech GmbH Revenue in Graft Versus Host Disease Treatment Business (2020-2025)
11.11.5 Neovii Biotech GmbH Recent Development
11.12 Novartis AG
11.12.1 Novartis AG Company Details
11.12.2 Novartis AG Business Overview
11.12.3 Novartis AG Graft Versus Host Disease Treatment Introduction
11.12.4 Novartis AG Revenue in Graft Versus Host Disease Treatment Business (2020-2025)
11.12.5 Novartis AG Recent Development
11.13 Ocugen, Inc.
11.13.1 Ocugen, Inc. Company Details
11.13.2 Ocugen, Inc. Business Overview
11.13.3 Ocugen, Inc. Graft Versus Host Disease Treatment Introduction
11.13.4 Ocugen, Inc. Revenue in Graft Versus Host Disease Treatment Business (2020-2025)
11.13.5 Ocugen, Inc. Recent Development
11.14 Pfizer Inc
11.14.1 Pfizer Inc Company Details
11.14.2 Pfizer Inc Business Overview
11.14.3 Pfizer Inc Graft Versus Host Disease Treatment Introduction
11.14.4 Pfizer Inc Revenue in Graft Versus Host Disease Treatment Business (2020-2025)
11.14.5 Pfizer Inc Recent Development
11.15 Pluristem Therapeutics Inc.
11.15.1 Pluristem Therapeutics Inc. Company Details
11.15.2 Pluristem Therapeutics Inc. Business Overview
11.15.3 Pluristem Therapeutics Inc. Graft Versus Host Disease Treatment Introduction
11.15.4 Pluristem Therapeutics Inc. Revenue in Graft Versus Host Disease Treatment Business (2020-2025)
11.15.5 Pluristem Therapeutics Inc. Recent Development
11.16 Samedan Ltd
11.16.1 Samedan Ltd Company Details
11.16.2 Samedan Ltd Business Overview
11.16.3 Samedan Ltd Graft Versus Host Disease Treatment Introduction
11.16.4 Samedan Ltd Revenue in Graft Versus Host Disease Treatment Business (2020-2025)
11.16.5 Samedan Ltd Recent Development
11.17 Sanofi SA
11.17.1 Sanofi SA Company Details
11.17.2 Sanofi SA Business Overview
11.17.3 Sanofi SA Graft Versus Host Disease Treatment Introduction
11.17.4 Sanofi SA Revenue in Graft Versus Host Disease Treatment Business (2020-2025)
11.17.5 Sanofi SA Recent Development
11.18 Soligenix, Inc.
11.18.1 Soligenix, Inc. Company Details
11.18.2 Soligenix, Inc. Business Overview
11.18.3 Soligenix, Inc. Graft Versus Host Disease Treatment Introduction
11.18.4 Soligenix, Inc. Revenue in Graft Versus Host Disease Treatment Business (2020-2025)
11.18.5 Soligenix, Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Graft Versus Host Disease Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Etanercept
Table 3. Key Players of Monoclonal Antibodies
Table 4. Key Players of Thalidomide
Table 5. Key Players of Tyrosine Kinase Inhibitors
Table 6. Key Players of mTOR Inhibitors
Table 7. Global Graft Versus Host Disease Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Graft Versus Host Disease Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Graft Versus Host Disease Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Graft Versus Host Disease Treatment Market Share by Region (2020-2025)
Table 11. Global Graft Versus Host Disease Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Graft Versus Host Disease Treatment Market Share by Region (2026-2031)
Table 13. Graft Versus Host Disease Treatment Market Trends
Table 14. Graft Versus Host Disease Treatment Market Drivers
Table 15. Graft Versus Host Disease Treatment Market Challenges
Table 16. Graft Versus Host Disease Treatment Market Restraints
Table 17. Global Graft Versus Host Disease Treatment Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Graft Versus Host Disease Treatment Market Share by Players (2020-2025)
Table 19. Global Top Graft Versus Host Disease Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Graft Versus Host Disease Treatment as of 2024)
Table 20. Ranking of Global Top Graft Versus Host Disease Treatment Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Graft Versus Host Disease Treatment Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Graft Versus Host Disease Treatment, Headquarters and Area Served
Table 23. Global Key Players of Graft Versus Host Disease Treatment, Product and Application
Table 24. Global Key Players of Graft Versus Host Disease Treatment, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Graft Versus Host Disease Treatment Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Graft Versus Host Disease Treatment Revenue Market Share by Type (2020-2025)
Table 28. Global Graft Versus Host Disease Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Graft Versus Host Disease Treatment Revenue Market Share by Type (2026-2031)
Table 30. Global Graft Versus Host Disease Treatment Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Graft Versus Host Disease Treatment Revenue Market Share by Application (2020-2025)
Table 32. Global Graft Versus Host Disease Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Graft Versus Host Disease Treatment Revenue Market Share by Application (2026-2031)
Table 34. North America Graft Versus Host Disease Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Graft Versus Host Disease Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Graft Versus Host Disease Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Graft Versus Host Disease Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Graft Versus Host Disease Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Graft Versus Host Disease Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Graft Versus Host Disease Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Graft Versus Host Disease Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Graft Versus Host Disease Treatment Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Graft Versus Host Disease Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Graft Versus Host Disease Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Graft Versus Host Disease Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Graft Versus Host Disease Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Graft Versus Host Disease Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Graft Versus Host Disease Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 49. AbbVie Inc. Company Details
Table 50. AbbVie Inc. Business Overview
Table 51. AbbVie Inc. Graft Versus Host Disease Treatment Product
Table 52. AbbVie Inc. Revenue in Graft Versus Host Disease Treatment Business (2020-2025) & (US$ Million)
Table 53. AbbVie Inc. Recent Development
Table 54. Acrofan Company Details
Table 55. Acrofan Business Overview
Table 56. Acrofan Graft Versus Host Disease Treatment Product
Table 57. Acrofan Revenue in Graft Versus Host Disease Treatment Business (2020-2025) & (US$ Million)
Table 58. Acrofan Recent Development
Table 59. Astellas Pharma Inc. Company Details
Table 60. Astellas Pharma Inc. Business Overview
Table 61. Astellas Pharma Inc. Graft Versus Host Disease Treatment Product
Table 62. Astellas Pharma Inc. Revenue in Graft Versus Host Disease Treatment Business (2020-2025) & (US$ Million)
Table 63. Astellas Pharma Inc. Recent Development
Table 64. Bristol-Myers Squibb Company Company Details
Table 65. Bristol-Myers Squibb Company Business Overview
Table 66. Bristol-Myers Squibb Company Graft Versus Host Disease Treatment Product
Table 67. Bristol-Myers Squibb Company Revenue in Graft Versus Host Disease Treatment Business (2020-2025) & (US$ Million)
Table 68. Bristol-Myers Squibb Company Recent Development
Table 69. ElsaLys Biotech SA Company Details
Table 70. ElsaLys Biotech SA Business Overview
Table 71. ElsaLys Biotech SA Graft Versus Host Disease Treatment Product
Table 72. ElsaLys Biotech SA Revenue in Graft Versus Host Disease Treatment Business (2020-2025) & (US$ Million)
Table 73. ElsaLys Biotech SA Recent Development
Table 74. F. Hoffmann-La Roche AG Company Details
Table 75. F. Hoffmann-La Roche AG Business Overview
Table 76. F. Hoffmann-La Roche AG Graft Versus Host Disease Treatment Product
Table 77. F. Hoffmann-La Roche AG Revenue in Graft Versus Host Disease Treatment Business (2020-2025) & (US$ Million)
Table 78. F. Hoffmann-La Roche AG Recent Development
Table 79. Johnson & Johnson Company Details
Table 80. Johnson & Johnson Business Overview
Table 81. Johnson & Johnson Graft Versus Host Disease Treatment Product
Table 82. Johnson & Johnson Revenue in Graft Versus Host Disease Treatment Business (2020-2025) & (US$ Million)
Table 83. Johnson & Johnson Recent Development
Table 84. Mallinckrodft PLC Company Details
Table 85. Mallinckrodft PLC Business Overview
Table 86. Mallinckrodft PLC Graft Versus Host Disease Treatment Product
Table 87. Mallinckrodft PLC Revenue in Graft Versus Host Disease Treatment Business (2020-2025) & (US$ Million)
Table 88. Mallinckrodft PLC Recent Development
Table 89. Merck & Co., Inc. Company Details
Table 90. Merck & Co., Inc. Business Overview
Table 91. Merck & Co., Inc. Graft Versus Host Disease Treatment Product
Table 92. Merck & Co., Inc. Revenue in Graft Versus Host Disease Treatment Business (2020-2025) & (US$ Million)
Table 93. Merck & Co., Inc. Recent Development
Table 94. Mesoblast Limited Company Details
Table 95. Mesoblast Limited Business Overview
Table 96. Mesoblast Limited Graft Versus Host Disease Treatment Product
Table 97. Mesoblast Limited Revenue in Graft Versus Host Disease Treatment Business (2020-2025) & (US$ Million)
Table 98. Mesoblast Limited Recent Development
Table 99. Neovii Biotech GmbH Company Details
Table 100. Neovii Biotech GmbH Business Overview
Table 101. Neovii Biotech GmbH Graft Versus Host Disease Treatment Product
Table 102. Neovii Biotech GmbH Revenue in Graft Versus Host Disease Treatment Business (2020-2025) & (US$ Million)
Table 103. Neovii Biotech GmbH Recent Development
Table 104. Novartis AG Company Details
Table 105. Novartis AG Business Overview
Table 106. Novartis AG Graft Versus Host Disease Treatment Product
Table 107. Novartis AG Revenue in Graft Versus Host Disease Treatment Business (2020-2025) & (US$ Million)
Table 108. Novartis AG Recent Development
Table 109. Ocugen, Inc. Company Details
Table 110. Ocugen, Inc. Business Overview
Table 111. Ocugen, Inc. Graft Versus Host Disease Treatment Product
Table 112. Ocugen, Inc. Revenue in Graft Versus Host Disease Treatment Business (2020-2025) & (US$ Million)
Table 113. Ocugen, Inc. Recent Development
Table 114. Pfizer Inc Company Details
Table 115. Pfizer Inc Business Overview
Table 116. Pfizer Inc Graft Versus Host Disease Treatment Product
Table 117. Pfizer Inc Revenue in Graft Versus Host Disease Treatment Business (2020-2025) & (US$ Million)
Table 118. Pfizer Inc Recent Development
Table 119. Pluristem Therapeutics Inc. Company Details
Table 120. Pluristem Therapeutics Inc. Business Overview
Table 121. Pluristem Therapeutics Inc. Graft Versus Host Disease Treatment Product
Table 122. Pluristem Therapeutics Inc. Revenue in Graft Versus Host Disease Treatment Business (2020-2025) & (US$ Million)
Table 123. Pluristem Therapeutics Inc. Recent Development
Table 124. Samedan Ltd Company Details
Table 125. Samedan Ltd Business Overview
Table 126. Samedan Ltd Graft Versus Host Disease Treatment Product
Table 127. Samedan Ltd Revenue in Graft Versus Host Disease Treatment Business (2020-2025) & (US$ Million)
Table 128. Samedan Ltd Recent Development
Table 129. Sanofi SA Company Details
Table 130. Sanofi SA Business Overview
Table 131. Sanofi SA Graft Versus Host Disease Treatment Product
Table 132. Sanofi SA Revenue in Graft Versus Host Disease Treatment Business (2020-2025) & (US$ Million)
Table 133. Sanofi SA Recent Development
Table 134. Soligenix, Inc. Company Details
Table 135. Soligenix, Inc. Business Overview
Table 136. Soligenix, Inc. Graft Versus Host Disease Treatment Product
Table 137. Soligenix, Inc. Revenue in Graft Versus Host Disease Treatment Business (2020-2025) & (US$ Million)
Table 138. Soligenix, Inc. Recent Development
Table 139. Research Programs/Design for This Report
Table 140. Key Data Information from Secondary Sources
Table 141. Key Data Information from Primary Sources
Table 142. Authors List of This Report


List of Figures
Figure 1. Graft Versus Host Disease Treatment Picture
Figure 2. Global Graft Versus Host Disease Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Graft Versus Host Disease Treatment Market Share by Type: 2024 VS 2031
Figure 4. Etanercept Features
Figure 5. Monoclonal Antibodies Features
Figure 6. Thalidomide Features
Figure 7. Tyrosine Kinase Inhibitors Features
Figure 8. mTOR Inhibitors Features
Figure 9. Global Graft Versus Host Disease Treatment Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Graft Versus Host Disease Treatment Market Share by Application: 2024 VS 2031
Figure 11. Acute GVHD Case Studies
Figure 12. Chronic GVHD Case Studies
Figure 13. Prophylaxis GVHD Case Studies
Figure 14. Graft Versus Host Disease Treatment Report Years Considered
Figure 15. Global Graft Versus Host Disease Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Graft Versus Host Disease Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Graft Versus Host Disease Treatment Market Share by Region: 2024 VS 2031
Figure 18. Global Graft Versus Host Disease Treatment Market Share by Players in 2024
Figure 19. Global Top Graft Versus Host Disease Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Graft Versus Host Disease Treatment as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Graft Versus Host Disease Treatment Revenue in 2024
Figure 21. North America Graft Versus Host Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Graft Versus Host Disease Treatment Market Share by Country (2020-2031)
Figure 23. United States Graft Versus Host Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Graft Versus Host Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Graft Versus Host Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Graft Versus Host Disease Treatment Market Share by Country (2020-2031)
Figure 27. Germany Graft Versus Host Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Graft Versus Host Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Graft Versus Host Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Graft Versus Host Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Graft Versus Host Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Graft Versus Host Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Graft Versus Host Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Graft Versus Host Disease Treatment Market Share by Region (2020-2031)
Figure 35. China Graft Versus Host Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Graft Versus Host Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Graft Versus Host Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Graft Versus Host Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Graft Versus Host Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Graft Versus Host Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Graft Versus Host Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Graft Versus Host Disease Treatment Market Share by Country (2020-2031)
Figure 43. Mexico Graft Versus Host Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Graft Versus Host Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Graft Versus Host Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Graft Versus Host Disease Treatment Market Share by Country (2020-2031)
Figure 47. Turkey Graft Versus Host Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Graft Versus Host Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Graft Versus Host Disease Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. AbbVie Inc. Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2020-2025)
Figure 51. Acrofan Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2020-2025)
Figure 52. Astellas Pharma Inc. Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2020-2025)
Figure 53. Bristol-Myers Squibb Company Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2020-2025)
Figure 54. ElsaLys Biotech SA Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2020-2025)
Figure 55. F. Hoffmann-La Roche AG Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2020-2025)
Figure 56. Johnson & Johnson Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2020-2025)
Figure 57. Mallinckrodft PLC Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2020-2025)
Figure 58. Merck & Co., Inc. Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2020-2025)
Figure 59. Mesoblast Limited Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2020-2025)
Figure 60. Neovii Biotech GmbH Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2020-2025)
Figure 61. Novartis AG Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2020-2025)
Figure 62. Ocugen, Inc. Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2020-2025)
Figure 63. Pfizer Inc Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2020-2025)
Figure 64. Pluristem Therapeutics Inc. Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2020-2025)
Figure 65. Samedan Ltd Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2020-2025)
Figure 66. Sanofi SA Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2020-2025)
Figure 67. Soligenix, Inc. Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2020-2025)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies